These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 20636879)

  • 1. Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin.
    Choi DH; Li C; Choi JS
    J Pharm Pharmacol; 2010 Jul; 62(7):908-14. PubMed ID: 20636879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats.
    Choi JS; Choi JS; Choi DH
    Pharmazie; 2013 Nov; 68(11):882-8. PubMed ID: 24380237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
    Yang SH; Choi JS; Choi DH
    Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin.
    Cho YA; Lee W; Choi JS
    Pharmazie; 2012 Feb; 67(2):124-30. PubMed ID: 22512082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats.
    Yang SH; Cho YA; Choi JS
    Acta Pharmacol Sin; 2011 Jul; 32(7):967-72. PubMed ID: 21666702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of myricetin on the bioavailability of carvedilol in rats.
    Lee W; Woo ER; Choi JS
    Pharm Biol; 2012 Apr; 50(4):516-22. PubMed ID: 22132944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of myricetin, an anticancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.
    Li C; Lim SC; Kim J; Choi JS
    Eur J Drug Metab Pharmacokinet; 2011 Sep; 36(3):175-82. PubMed ID: 21442417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: possible role of CYP3A4 and P-glycoprotein inhibition by myricetin.
    Choi SJ; Shin SC; Choi JS
    Arch Pharm Res; 2011 Feb; 34(2):309-15. PubMed ID: 21380815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by baicalein.
    Li C; Kim M; Choi H; Choi J
    Arch Pharm Res; 2011 Nov; 34(11):1965-72. PubMed ID: 22139696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin.
    Hong SP; Yang JS; Han JY; Ha SI; Chung JW; Koh YY; Chang KS; Choi DH
    J Pharm Pharmacol; 2011 Jan; 63(1):129-35. PubMed ID: 21189658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of P-glycoprotein and CYP3A4 inhibition by baicalein.
    Cho YA; Choi JS; Burm JP
    Pharmacol Rep; 2011; 63(4):1066-73. PubMed ID: 22001996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of pioglitazone on the pharmacokinetics of nifedipine and its main metabolite, dehydronifedipine, in rats.
    Choi JS; Choi I; Choi DH
    Eur J Drug Metab Pharmacokinet; 2016 Jun; 41(3):231-8. PubMed ID: 25549928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin.
    Choi DH; Choi JS; Li C; Choi JS
    Pharmacol Rep; 2011; 63(6):1574-82. PubMed ID: 22358108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of licochalcone A on the bioavailability and pharmacokinetics of nifedipine in rats: possible role of intestinal CYP3A4 and P-gp inhibition by licochalcone A.
    Choi JS; Choi JS; Choi DH
    Biopharm Drug Dispos; 2014 Oct; 35(7):382-90. PubMed ID: 24903704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of silybinin, CYP3A4 and P-glycoprotein inhibitor in vitro, on the bioavailability of loratadine in rats.
    Li C; Lee MY; Choi JS
    Pharmazie; 2010 Jul; 65(7):510-4. PubMed ID: 20662320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of myricetin on cytochrome P450 isoforms CYP1A2, CYP2C9 and CYP3A4 in rats.
    Guo YJ; Zheng SL
    Pharmazie; 2014 Apr; 69(4):306-10. PubMed ID: 24791597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin.
    Choi JS; Piao YJ; Kang KW
    Arch Pharm Res; 2011 Apr; 34(4):607-13. PubMed ID: 21544726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin.
    Hong SP; Chang KS; Koh YY; Choi DH; Choi JS
    Arch Pharm Res; 2009 Oct; 32(10):1447-52. PubMed ID: 19898809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.
    Lee CR; Pieper JA; Hinderliter AL; Blaisdell JA; Goldstein JA
    Pharmacotherapy; 2003 Jun; 23(6):720-5. PubMed ID: 12820813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.
    Zaidenstein R; Soback S; Gips M; Avni B; Dishi V; Weissgarten Y; Golik A; Scapa E
    Ther Drug Monit; 2001 Aug; 23(4):369-73. PubMed ID: 11477318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.